Glenmark gets USFDA nod for Fingolimod capsules
Glenmark Pharmaceuticals has received a final nod from the health regulator for Fingolimod capsules for the treatment of adult patients with relapsing forms of multiple sclerosis.

"Glenmark Pharmaceuticals Inc, USA has been granted final approval by the United States Food and Drug Administration (USFDA) for Fingolimod Capsules, 0.5 mg, the generic version of Gilenya capsules, 0.5 mg, of Novartis Pharmaceuticals Corporation," the drug major said.
Dr. T●●●●z H●●●●●●i and 1 others like this2 shares